Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Morgan Stanley cuts rating on BP

(Sharecast News) - Morgan Stanley has downgraded BP and reiterated its 'overweight' rating for rival Shell, in a note assessing European the energy sector. The Wall Street bank argued that the sector's fortunes "remain closely tied to oil markets, which we expect to enter a meaningful surplus after the summer.

"We foresee downside risk to earnings and buybacks, upside risk to net debt and do not find valuations compelling."

Shell remains the sector's top pick, followed by TotalEnergies, which Morgan Stanley upgraded to 'overweight' from 'equal weight'.

But BP was trimmed to 'underweight' from 'equal weight'.

Morgan Stanley said: "BP laid out an ambitious plan with major cost savings, capex cuts, disposal plans and a shift back to oil and gas.

"However, that was only part of the issue. More confidence on earnings delivery and an improved balance sheet takes time, and is contingent on execution of the current plan, which is a more difficult task to deliver amid lower oil prices."

It concluded: "We see a combination of elevated gearings versus peers; larger downside risk to consensus expectations than peers; and a premium valuation.

"Altogether that does not screen as particularly compelling to us in the context of lower oil prices and a preference for defensive stores, and we downgrade the stock."

As at 1330 BST, BP was up 3% at 384.1p, while Shell was 2% higher at 2,516p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.